Han Yue, Song Wenqian, Duan Huxinyue, Xiao Xingyue, Yao Chenhao, Yang Dan, Wu Chunjie, Wang Zhenxing, He Yacong
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; Department of pharmacy,Sichuan clinical research center for cancer, Sichuan cancer hospital & Institute, Sichuan cancer center, Affiliated cancer hospital of university of electronic science and technology of china, Chengdu , China.
J Ethnopharmacol. 2025 Aug 30:120485. doi: 10.1016/j.jep.2025.120485.
Musk (Moschus Moschiferus) is regarded as a key drug for treating brain injury-related nerve damage in both traditional Chinese medicine and Tibetan medicine. According to the theory of traditional Chinese medicine, musk has the characteristics of being pungent and warm, and acts on the heart and spleen meridians, with the effects of awakening the brain and opening the orifices, as well as promoting blood circulation and removing blood stasis. This makes it an important drug for treating acute brain injuries such as closed coma and stroke with phlegm obstruction. Modern research has revealed that musk has multiple neuroprotective mechanisms and anti-inflammatory/antioxidant effects. These findings support its therapeutic potential in targeting neuronal injury pathways in the prevention and treatment of HACE, and further translational research is warranted.
This study aimed to investigate the neuroprotective properties of musk and uncovering the mechanisms through which it may exert its beneficial effects against HACE.
The constituents of musk were analyzed using Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS). Additionally, network pharmacology and proteomic profiling were applied to identify possible molecular targets and associated signaling pathways. In vivo experiments were carried out using a rat model simulating an altitude of 6000 meters over a 48-h period, while in vitro investigations involved exposing cultured microglial cells to hypoxia for 6 h. The effectiveness and mode of action of musk were evaluated using a range of experimental techniques, including brain water content analysis via brain water content (BWC), histopathological examination (HE), Enzyme-linked immunosorbent assay (ELISA), Western blotting (WB), transmission electron microscopy (TEM), and flow cytometry (FCM).
The UPLC-MS analysis identified 117 active compounds within musk. The tumor necrosis factor (TNF) signaling pathway might play a central role in mediating the protective effects of musk through the network pharmacology and proteomics combination. Pharmacodynamic results showed that pretreatment with musk significantly improved HACE-related neurological deficits in rats, reduced brain swelling, and protected cerebral tissue structure. Moreover, musk substantially decreased levels of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), and suppressed the expression of aquaporin-4 (AQP4) and hypoxia-inducible factor-1α (HIF-1α). TEM imaging and Western blot assays collectively confirmed that musk could counteract hypoxia-induced necroptosis in microglial cells. In vitro studies further revealed that musk preserved microglial cell viability, restrained inflammatory mediator release, and interrupted the TNF-α/RIPK1-mediated necroptotic pathway. Importantly, the administration of exogenous TNF-α partially diminished the protective effects of musk, supporting the conclusion that its mechanism involves the TNF-α/RIPK1 signaling cascade.
Our findings indicate that musk alleviates HACE by suppressing necroptotic processes through modulation of the TNF-α/RIPK1 pathway. These results offer a promising therapeutic approach for managing high-altitude illnesses and provide important evidence for the scientific validation and clinical application of traditional herbal medicines.
麝香(Moschus Moschiferus)在中医和藏医中均被视为治疗脑损伤相关神经损伤的关键药物。根据中医理论,麝香具有辛温之性,归心、脾经,有醒脑开窍、活血化瘀之功。这使其成为治疗诸如闭合性昏迷和痰阻型中风等急性脑损伤的重要药物。现代研究表明,麝香具有多种神经保护机制以及抗炎/抗氧化作用。这些发现支持了其在预防和治疗高原脑水肿(HACE)中针对神经元损伤途径的治疗潜力,值得进一步开展转化研究。
本研究旨在探究麝香的神经保护特性,并揭示其对高原脑水肿发挥有益作用的机制。
采用超高效液相色谱-质谱联用(UPLC-MS)分析麝香的成分。此外,运用网络药理学和蛋白质组学分析来确定可能的分子靶点及相关信号通路。体内实验使用模拟海拔6000米的大鼠模型,持续48小时;体外研究则将培养的小胶质细胞置于缺氧环境6小时。通过一系列实验技术评估麝香的有效性和作用方式,包括脑含水量(BWC)分析、组织病理学检查(HE)、酶联免疫吸附测定(ELISA)、蛋白质印迹法(WB)、透射电子显微镜(TEM)和流式细胞术(FCM)。
UPLC-MS分析在麝香中鉴定出117种活性化合物。通过网络药理学和蛋白质组学相结合的方法发现,肿瘤坏死因子(TNF)信号通路可能在介导麝香的保护作用中发挥核心作用。药效学结果显示,麝香预处理可显著改善大鼠与高原脑水肿相关的神经功能缺损,减轻脑肿胀,并保护脑组织结构。此外,麝香可显著降低促炎细胞因子如肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和白细胞介素-1β(IL-1β)的水平,并抑制水通道蛋白-4(AQP4)和缺氧诱导因子-1α(HIF-1α)的表达。TEM成像和蛋白质印迹分析共同证实,麝香可对抗缺氧诱导的小胶质细胞坏死性凋亡。体外研究进一步表明,麝香可维持小胶质细胞活力,抑制炎症介质释放,并阻断TNF-α/RIPK1介导的坏死性凋亡途径。重要的是,外源性TNF-α的给药部分削弱了麝香的保护作用,支持其作用机制涉及TNF-α/RIPK1信号级联反应的结论。
我们的研究结果表明,麝香通过调节TNF-α/RIPK1途径抑制坏死性凋亡过程来减轻高原脑水肿。这些结果为管理高原疾病提供了一种有前景的治疗方法,并为传统草药的科学验证和临床应用提供了重要证据。